Exploring the Cystic Fibrosis Lung Microbiome: Making the Most of a Sticky Situation

Overview

Journal J Pediatric Infect Dis Soc

Publisher Oxford University Press

Specialties Infectious Diseases
Pediatrics

Date 2022 Sep 7

PMID 36069903

Authors

Christina S Thornton

Nicole Acosta

Michael G Surette

Michael D Parkins

Affiliations

Soon will be listed here.

Abstract

Chronic lower respiratory tract infections are a leading contributor to morbidity and mortality in persons with cystic fibrosis (pwCF). Traditional respiratory tract surveillance culturing has focused on a limited range of classic pathogens; however, comprehensive culture and culture-independent molecular approaches have demonstrated complex communities highly unique to each individual. Microbial community structure evolves through the lifetime of pwCF and is associated with baseline disease state and rates of disease progression including occurrence of pulmonary exacerbations. While molecular analysis of the airway microbiome has provided insight into these dynamics, challenges remain including discerning not only "who is there" but "what they are doing" in relation to disease progression. Moreover, the microbiome can be leveraged as a multi-modal biomarker for both disease activity and prognostication. In this article, we review our evolving understanding of the role these communities play in pwCF and identify challenges in translating microbiome data to clinical practice.

Citing Articles

Highly Effective Modulator Therapy: Implications for the Microbial Landscape in Cystic Fibrosis.

Valladares K, Jones L, Barnes J, Krick S Int J Mol Sci. 2024; 25(22).

PMID: 39595943 PMC: 11594123. DOI: 10.3390/ijms252211865.

Early nasal microbiota and subsequent respiratory tract infections in infants with cystic fibrosis.

Steinberg R, Mostacci N, Kieninger E, Frauchiger B, Casaulta C, Usemann J Commun Med (Lond). 2024; 4(1):246.

PMID: 39580540 PMC: 11585651. DOI: 10.1038/s43856-024-00616-6.

Microbiome and metabolome patterns after lung transplantation reflect underlying disease and chronic lung allograft dysfunction.

Martin C, Mahan K, Wiggen T, Gilbertsen A, Hertz M, Hunter R Microbiome. 2024; 12(1):196.

PMID: 39385282 PMC: 11462767. DOI: 10.1186/s40168-024-01893-y.

Metagenomics Applied to the Respiratory Mycobiome in Cystic Fibrosis.

Angebault C, Botterel F Mycopathologia. 2024; 189(5):82.

PMID: 39264513 PMC: 11392981. DOI: 10.1007/s11046-024-00887-6.

in chronic lung disease: untangling the dysregulated host immune response.

Nickerson R, Thornton C, Johnston B, Lee A, Cheng Z Front Immunol. 2024; 15:1405376.

PMID: 39015565 PMC: 11250099. DOI: 10.3389/fimmu.2024.1405376.

References

Muhlebach M, Hatch J, Einarsson G, McGrath S, Gilipin D, Lavelle G . Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study. Eur Respir J. 2018; 52(1). PMC: 6376871. DOI: 10.1183/13993003.00242-2018. View

Kirst M, Baker D, Li E, Abu-Hasan M, Wang G . Upper versus lower airway microbiome and metagenome in children with cystic fibrosis and their correlation with lung inflammation. PLoS One. 2019; 14(9):e0222323. PMC: 6752789. DOI: 10.1371/journal.pone.0222323. View

Hisert K, Heltshe S, Pope C, Jorth P, Wu X, Edwards R . Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections. Am J Respir Crit Care Med. 2017; 195(12):1617-1628. PMC: 5476912. DOI: 10.1164/rccm.201609-1954OC. View

Stafler P, Davies J, Balfour-Lynn I, Rosenthal M, Bush A . Bronchoscopy in cystic fibrosis infants diagnosed by newborn screening. Pediatr Pulmonol. 2011; 46(7):696-700. DOI: 10.1002/ppul.21434. View

Jain K, Wainwright C, Smyth A . Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. Cochrane Database Syst Rev. 2018; 9:CD009530. PMC: 6513589. DOI: 10.1002/14651858.CD009530.pub4. View

Gao B, Gallagher T, Zhang Y, Elbadawi-Sidhu M, Lai Z, Fiehn O . Tracking Polymicrobial Metabolism in Cystic Fibrosis Airways: Metabolism and Physiology Are Influenced by -Derived Metabolites. mSphere. 2018; 3(2). PMC: 5917424. DOI: 10.1128/mSphere.00151-18. View

Chin M, De Zoysa M, Slinger R, Gaudet E, Vandemheen K, Chan F . Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations. J Cyst Fibros. 2014; 14(4):482-9. PMC: 7105172. DOI: 10.1016/j.jcf.2014.11.009. View

Harris J, De Groote M, Sagel S, Zemanick E, Kapsner R, Penvari C . Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci U S A. 2007; 104(51):20529-33. PMC: 2154465. DOI: 10.1073/pnas.0709804104. View

Coburn B, Wang P, Diaz Caballero J, Clark S, Brahma V, Donaldson S . Lung microbiota across age and disease stage in cystic fibrosis. Sci Rep. 2015; 5:10241. PMC: 4431465. DOI: 10.1038/srep10241. View

10.

Pust M, Wiehlmann L, Davenport C, Rudolf I, Dittrich A, Tummler B . The human respiratory tract microbial community structures in healthy and cystic fibrosis infants. NPJ Biofilms Microbiomes. 2020; 6(1):61. PMC: 7738502. DOI: 10.1038/s41522-020-00171-7. View

11.

Lu J, Carmody L, Opron K, Simon R, Kalikin L, Caverly L . Parallel Analysis of Cystic Fibrosis Sputum and Saliva Reveals Overlapping Communities and an Opportunity for Sample Decontamination. mSystems. 2020; 5(4). PMC: 7343308. DOI: 10.1128/mSystems.00296-20. View

12.

Regelmann W, Elliott G, Warwick W, Clawson C . Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis. 1990; 141(4 Pt 1):914-21. DOI: 10.1164/ajrccm/141.4_Pt_1.914. View

13.

Layeghifard M, Li H, Wang P, Donaldson S, Coburn B, Clark S . Microbiome networks and change-point analysis reveal key community changes associated with cystic fibrosis pulmonary exacerbations. NPJ Biofilms Microbiomes. 2019; 5(1):4. PMC: 6341074. DOI: 10.1038/s41522-018-0077-y. View

14.

Lamoureux C, Guilloux C, Courteboeuf E, Gouriou S, Beauruelle C, Hery-Arnaud G . , a Sentinel Species of Antibiotic Resistance in Cystic Fibrosis Respiratory Niche?. Microorganisms. 2021; 9(6). PMC: 8230849. DOI: 10.3390/microorganisms9061275. View

15.

Sherrard L, Tunney M, Elborn J . Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. Lancet. 2014; 384(9944):703-13. DOI: 10.1016/S0140-6736(14)61137-5. View

16.

Fodor A, Klem E, Gilpin D, Elborn J, Boucher R, Tunney M . The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One. 2012; 7(9):e45001. PMC: 3458854. DOI: 10.1371/journal.pone.0045001. View

17.

Cuevas-Ocana S, Laselva O, Avolio J, Nenna R . The era of CFTR modulators: improvements made and remaining challenges. Breathe (Sheff). 2020; 16(2):200016. PMC: 7714553. DOI: 10.1183/20734735.0016-2020. View

18.

Sibley C, Grinwis M, Field T, Eshaghurshan C, Faria M, Dowd S . Culture enriched molecular profiling of the cystic fibrosis airway microbiome. PLoS One. 2011; 6(7):e22702. PMC: 3145661. DOI: 10.1371/journal.pone.0022702. View

19.

Lim Y, Schmieder R, Haynes M, Willner D, Furlan M, Youle M . Metagenomics and metatranscriptomics: windows on CF-associated viral and microbial communities. J Cyst Fibros. 2012; 12(2):154-64. PMC: 3534838. DOI: 10.1016/j.jcf.2012.07.009. View

20.

Nguyen M, Sharma A, Wu W, Gomi R, Sung B, Hospodsky D . The fermentation product 2,3-butanediol alters P. aeruginosa clearance, cytokine response and the lung microbiome. ISME J. 2016; 10(12):2978-2983. PMC: 5148197. DOI: 10.1038/ismej.2016.76. View